Cancer Primary Antibodies


 

 

Cancer Overview


Cancer is a term used for diseases involving abnormal cell growth with the potential to invade other tissues. Over 100 different types of cancer have been identified. Most cancers are named for the organ or type of cell in which they start. Cancer cells can spread to other parts of the body through the blood and lymph systems. The initiation and progression of cancer has traditionally been seen as a genetic disease; but in the past decade numerous publications have shown the involvement of epigenetic abnormalities in cancer. The reversible nature of some epigenetic aberrations has led to the rise of the promising field of epigenetic therapy in cancer treatment. Protein phosphorylation plays a significant role in a wide range of cellular processes including cell growth and proliferation. An aberrant phosphorylation pattern is another important tool in cancer research. At Rockland, we have developed a vast and diverse portfolio of phospho specific antibodies to enable scientists to track and quantify phospho proteins using a wide range of techniques such as phospho immunoprecipitation, western blot, flow cytometry, immunohistochemistry and immunofluorescence.

Rockland has developed a number of highly validated antibodies for Cancer research, a variety of these antibodies have been developed in partnership with the, Emory University and other institutions.  By combining basic and applied research principles and working closely with life science researchers Rockland develops highly characterized antibodies that recognize relevant cancer targets to facilitate biomedical research.

Our reagents are tested in numerous applications to perform as specified, delivering highest quality tools for innovative research. Rockland’s cancer research antibodies yield reproducible results and lead to significant advances in the field.

Featured Antibodies

 

CREB pS133 Antibody

  

Anti-NFKB p65 Rel-A pS276

   

SMAD3 pS423 pS425 Antibody

 

Anti-CREB pS133

(RABBIT) Antibody
600-401-270
  

 

Anti-NFKB p65 (Rel A) pS276

(RABBIT) Antibody
 100-401-264 

 

Anti-SMAD3 pS423 pS425
(RABBIT) Antibody
 600-401-919 

 

 

 

Cancer Primary

  

 


 

Cancer Tools

 

Rockland offers a comprehensive variety of antibodies and antibody-based tools for the numerous methods needed in cancer research. Our products are developed to make a difference in ongoing research. We know through these efforts future generations will benefit from the discoveries made using Rockland antibody products.

 

 

Tools and Strategies Driving Cancer Immunotherapy

 

Rockland and The Scientist bring together a panel of experts who will delve into the hope and hype in an effort to educate the audience about the new findings in cancer immunotherapy.

 

With speakers Dr. Jedd Wolchok, Chief of Melanoma & Immunotherapeutics Service at Memorial Sloan-Kettering Cancer Center and Dr. Tibor Keler, Senior Vice President and Chief Scientific Officer at Celldex Therapeutics.

 

 

 


MEK and ERK Antibodies

 

 

The Ras-Raf-MEK-ERK Pathway is a critical cell signaling pathway with numerous implications for cancer biology and therapeutic development. Like the AKT-signaling pathway, this signaling cascade is part of the MAPK pathway that plays a role in the regulation of various cellular processes including proliferation, differentiation, development, learning, cell survival and, under some conditions, also apoptosis. Many of the mechanisms and known but not completely understood. Faulty regulation or function of multiple components in the pathway are observed in cancer cells. In fact, the activity of the Ras-Raf-MEK-ERK cascade is estimated to be increased in about one-third of all human cancers. Both MEK and ERK are phosphorylated by B-Raf in nearly all melanoma cancers.



 

PARP1 Antibodies in Collaboration with MD Anderson Cancer Center

 

In collaboration with MD Anderson Cancer Center, Rockland has developed and validated a highly specific toolkit to analyze PARP1 in a panel of control and siRNA knockdown cell lysates by multiple immunoassays. We can specifically and quantitatively distinguish PARP1 from 17 other PARP family members using highly specific antibodies and optimized methods.  Poly (ADP-ribose) polymerase-1 (PARP1) is a chromatin associated, ADP-ribosylating enzyme essential for multiple cellular functions, including cardiac remodeling, vasoconstriction, regulation of astrocyte and microglial function, long term memory, aging, transcription regulation, and DNA repair. More recently, it has been implicated in a new form of cell death termed parthanatos.  PARP1 can also promote tissue survival by shifting the balance of cell death programs between autophagy and necrosis. Since PARP1 can promote tumorigenicity, it has gained traction as a therapeutic target in cancer. In that regard, clinical studies have shown vulnerability to PARP inhibitors in DNA repair defective cancers. One of the difficulties in analyzing PARP1 activity is the promiscuity of the reagents toward other PARP family members.

Furthermore, the ability to examine multiple tissue samples in parallel has been limited.  In this study, we developed highly sensitive and specific antibodies against PARP1 fragments. Using siRNAs against 18 PARP family members, we validated antibody specificity by western blotting and nanoimmunoassay (NIA). NIA is a highly sensitive platform capable of screening up to 96 cancer samples at sub-microliter volume. Moreover, this platform permits quantitative analysis of non-modified PARP1 as well as post-translational modifications such as PARylation and phosphorylation using a single antibody for the measurement of all species. This workflow will be amenable to a wide range of protein targets, ushering in a new frontier in diagnostic analysis.

PARP1 Antibodies


 

 


HER2 Signaling

 

HER2 (human epidermal growth factor receptor 2) is a member of the epidermal growth factor receptor (HER/EGFR/ERBB) family. It is also called ERBB2, CD340 or proto-oncogene Neu. The protein is a receptor tyrosine kinase located on the plasma membrane of cells. Activation of the tyrosine kinase promotes cell proliferation and suppresses apoptosis. HER2 can dimerize with any other member of the ErbB family, which results in auto-phosphorylation of tyrosine residues and activation of signaling pathways. The signal is then transferred via PI3K/Akt, RAS/MEK/MAPK and STAT kinase that can be detected using Rockland’s phospho-specific antibodies to accurately determine activation of the pathway. Based on the Human Protein Reference Database (HPRD), HER2 interacts with more than 50 proteins directly.

 

HER2 is over expressed in a significant proportion of cancer patients resulting in an increased disease recurrence and poor prognosis. Therefore an early diagnosis of the HER2 status in the tumors is necessary to decide the appropriate treatment. Furthermore, in breast cancer HER2 is over expressed in a variety of different tumors which makes it a target for immunotherapy of certain patients. The antibody Trastuzumab (Herceptin) which recognizes HER2 was approved for the treatment of HER2 positive breast cancer patients in 1998. The original approval was for treatment of HER2 positive metastatic breast tumors. Later studies have shown that Herceptin is also beneficial for early stage HER2 positive tumor patients and it is approved as an adjuvant treatment. Additionally the antibody is now approved also for other HER2 positive tumors (metastatic gastric adenocarcinoma). 

  


 

Quality Production


Methods for antigen design and antibody generation, purification and validation have advanced over time to allow the generation of antibodies against a wide range of targets, regardless of their biochemical characteristics or natural abundance. Each step of the antibody development process is completed within our laboratories resulting in unsurpassed repeatability in antibody performance.  Each component used in our manufacturing process is developed within our own facilities, ensuring that each step of the process can be certified and verified multiple times. Our goal is to provide accountability and repeatable test results with each antibody we develop.

 


 

Cancer Antibody Applications


Cancer Western Blot Assays
Cancer Immunoprecipitation Assays
Cancer ELISA
Cancer FLISA
Cancer Immunohistochemistry Assays

Cancer Immunofluorescence Assays

Protect your results with Rockland antibodies.  Compromise Elsewhere.

 

For more information or a custom quote, contact us today!

 

 

 

 

NCI Validated Antibodies

 

  

Epigenetic Button

 

 

 

 

ATM Antibodies

ATM codes for a protein kinase that acts as a master regulator of cellular responses to DNA double-strand breaks. ATM is normally inactive and the question of how it is activated in the event of DNA damage (due to ionizing radiation for instance) is central to understanding its function.